The Lyme Disease and Related Tick-Borne Illness Diagnosis and Treatment Act aims to enhance patient access to diagnostics and treatments for Lyme disease and related tick-borne illnesses in Pennsylvania. The bill recognizes the state's high incidence of Lyme disease, with approximately 100,000 cases reported annually, and emphasizes the importance of early diagnosis and appropriate treatment to mitigate chronic symptoms. The act mandates that health insurance policies and government programs provide coverage for all diagnostic testing, including comprehensive testing for Lyme disease and tick testing, as well as prescribed treatments, which may include both short-term and long-term antibiotic therapies.

Additionally, the act requires the Department of Health to conduct educational campaigns for healthcare practitioners and the public, develop culturally appropriate educational materials, and establish a statewide registry for tracking tick testing and Lyme disease diagnoses. Insurers are also required to report on the implementation of these coverage provisions by January 1, 2027. The act is set to take effect 60 days after its passage, with the intention of significantly reducing the incidence of Lyme disease and improving public awareness and prevention strategies.